App note

Early target and functional affinity insights guide candidate selection during lead optimization

App note /

Accelerated Trastuzumab clone selection by early all-in-one insights into yield, Fab & functional Fc affinity, confirmed by structural data. The continuous analytical waltz toward the optimal antibody candidate Lead optimization is an iterative and complex process involving cycles of design, production, purification, and characterization. As development progresses assays become more time-consuming, costly, and technically demanding […]

Early target and functional affinity insights guide candidate selection during lead optimization Read More »

Precision Patient Selection in Clinical Trials: Cutting Costs and Boosting Success in Biologics and CAR-T Therapies

App note /

Why Clinical Trial Costs Are Skyrocketing Clinical trials sit at the heart of drug development, but their budgets are climbing faster than ever—with Phase III trials now frequently costing between $20 and $100 million. A big chunk of these costs stems from the sheer size and scope of patient recruitment and monitoring. When the wrong

Precision Patient Selection in Clinical Trials: Cutting Costs and Boosting Success in Biologics and CAR-T Therapies Read More »

Leading to patient-dependent affinity

App note /

“From buffer to Patients: Affinity assay predicting therapeutic behaviour in patients” Why Measuring Affinity in Native Plasma Matters for Therapeutic Development Affinity defines how strongly a therapeutic antibody binds to its target — and it is one of the most important parameters influencing efficacy, dosing, and clinical performance. Traditionally, affinity is measured in purified systems.

Leading to patient-dependent affinity Read More »

De-risk your sdAbs pipeline with superior selection in physiological conditions

App note /

Kinetic affinity comparison of candidates under actual clinical conditions for more predictive development Singledomain antibodies (sdAbs) have an improved capacity to penetrate tissues and reach obscured targets, making them powerful alternatives to conventional antibodies as therapeutic, whether it’s an inhibiting or neutralising function, or as the high precision binder in CAR-T therapy. Although these may

De-risk your sdAbs pipeline with superior selection in physiological conditions Read More »